title: Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats.
abstract: This study describes the effects of intra-lateral septal infusions of different doses of the mGluR5 antagonist MTEP in the DRL-72 s paradigm and the elevated plus-maze test in rats, two behavioral models known to be sensitive to antidepressant-like and anxiolytic-like drug effects, respectively. Intra-lateral septal infusions of MTEP induced a dose-dependent (5.0 microg/microl, P<0.05; 10.0 microg/microl, P<0.05) increase in reinforced lever presses and a cohesive rightward shift of the inter-response time distribution (5.0 microg/microl, P<0.05; 10.0 microg/microl, P<0.05). These effects are indicative of antidepressant-like actions of the compound. Desipramine, a prototypical antidepressant drug, induced (5.0 microg/microl; P<0.05) similar effects. In the elevated plus-maze test, intra-lateral septal infusions of MTEP (5.0 microg/microl, P<0.05; 10.0 microg/microl, P<0.05) increased the exploration of the open arms without affecting locomotion. This anxiolytic-like effect was similar to that observed with the infusion of the benzodiazepine midazolam (10.0 microg/microl; P<0.05) in the same brain area. It is concluded that intra-lateral septal infusions of the mGlu5 receptor antagonist MTEP produced antidepressant-like actions or anxiolytic-like effects in male rats.
authors.affiliation: Laboratorio de Psicobiología y Etología, Instituto de Investigaciones Psicológicas, Universidad Veracruzana, Jalapa, Veracruz, México. mimoli@todito.com
authors.forename: Miguel
authors.initials: M
authors.lastname: Molina-Hernández
authors.forename: Norma Patricia
authors.initials: NP
authors.lastname: Tellez-Alcántara
authors.forename: Julián
authors.initials: J
authors.lastname: Pérez-García
authors.forename: Jorge Iván
authors.initials: JI
authors.lastname: Olivera-Lopez
authors.forename: M Teresa
authors.initials: MT
authors.lastname: Jaramillo
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000523:psychology; D003216:Conditioning, Operant / Q000187:drug effects; D003891:Desipramine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D008297:Male; D008845:Microinjections; D008874:Midazolam / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D012055:Reinforcement Schedule; D012686:Septal Nuclei / Q000502:physiology*; D013238:Stereotaxic Techniques; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: C472365:3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; C578937:Grm5 protein, rat; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D013844:Thiazoles; D008874:Midazolam; D003891:Desipramine